A French Unviversity (Technology Transfer Office) offers new cell therapy for acute GVHD (graft versus host disease).

OFFER from France, reference: TOFR20171005002, valid from 30-11-2017 untill 06-12-2018

Technology
  • Title:
    A French Unviversity (Technology Transfer Office) offers new cell therapy for acute GVHD (graft versus host disease).
  • Start date:
    30 november 2017 (3 weken geleden)
  • End date:
    6 december 2018
  • Summary:
    A French University (Technology Transfer Office) offers new cell therapy for acute GVHD (graft versus host disease). The innovation is based on an antigen-specific T regulatory cells that can be activated after the transplantation to prevent and/or treat GvHD without impairing anti-tumor effect.
    The TTO of this University is looking for companies to license in this technology or to collaborate in its development.
  • Description:
    The French TTO (Technology Transfer Office) is acting on behalf of an established public laboratory of a university of the Paris region.

    Hematopoietic stem cell transplantation (HSCT) is an established procedure for many acquired and congenital disorders of the hematopoietic system (more than 40000 transplants annually reported in Europe).

    Acute graft versus host disease (GvHD) is the main source of morbidity and mortality for patients after allogeneic HSCT (20 to 90% in severe cases) and has currently no specific and effective treatment.

    This disease is caused by the reaction of conventional T cells contained in the grafted hematopoietic stem cells against host. Allogenic Tregs have been used in several recent clinical trials to prevent GvHD but their efficiency is limited.

    Tregs developed by this offer are specific to an irrelevant antigen (not present in host or donor) and can be activated after transplantation at a chosen time by administration of the irrelevant peptide to the transplanted patient.

    With this inducible system, conventional T cells can elicit their anti-tumor effect before being suppressed by antigenactivated Tregs which prevent GvHD, thus optimizing the anti-tumor therapy and improving HSCTs outcomes.

    The applications are :
    - Prevention of acute GvHD
    - Treatment of acute GvHD
    - Allogenic Hematopoietic Stem Cell Transplantation
    - Other diseases caused by pathological T cells (autoimmune diseases, organ transplant rejection).

    The TTO of this University is looking for companies to license in this technology or to collaborate in its development.

Partner Sought
  • Type of Partnership Considered:
    License agreement, Research cooperation agreement
  • Technical Specification or Expertise Sought:

    The partner sought could be an university or a company interested in a license agreement or a research cooperation agreement or a technical cooperation agreement

    SME 11-50,University,R&D Institution,SME <10,>500 MNE,251-500,SME 51-250,>500

Organisation
  • Development stage:
    Available for demonstration
  • IPR Status:
    Patents granted
  • Market keywords:
    Therapeutic services
  • Technology keywords:
    Cytology, Cancerology, Oncology
    Cellular and Molecular Biology
  • NACE keywords:
    Research and experimental development on biotechnology
  • Advantages and Innovations:
    - 1st safe antigen-specific Tregs
    - Good balance of anti-tumor vs GvHD
    - Better efficiency than Allo Tregs
    - No global immunosuppression
    - Inducible system allowing Graft-versus- Tumor effect optimization
    - GMP-compliant Treg isolation procédure
Client
  • Type and Size of Organisation:
    Industry SME 50-249
  • Already Engaged in Trans-National Cooperation
    Ja
  • Year Established:
    2012
  • Turnover:
    1 - 10M
  • Country of origin:
    France
  • Languages spoken
    • English
    • French